International Journal of Hematology and Oncology 2021, Vol 31, Num 4 Page(s): 239-245
Comparison of Efficacies of Dose Dense Paclitaxel Plus Carboplatin and Conventional Paclitaxel Plus Carboplatin in the Treatment of Epithelial Ovarian Cancer

Veli SUNAR1, Vakkas KORKMAZ2, Koray ASLAN3, Caner KOSE4, Furkan SARICI5, Zafer ARIK6, Mehmet Mutlu MEYDANLI7

1Aydın Atatürk State Hospital, Medical Oncology Clinic, Aydın, TURKEY
2Ankara Etlik Zübeyde Hanım Training and Research Hospital, Gynecologic Oncology Clinic, Ankara, TURKEY
3Ankara City Hospital, Gynecologic Oncology Clinic, Ankara, TURKEY
4Ankara Etlik Zübeyde Hanım Training and Research Hospital, Obstetric and Gynecology Clinic, Ankara, TURKEY
5Medicana International Ankara Hospital, Medical Oncology Clinic, Ankara, TURKEY
6Hacettepe University Faculty of Medicine, Department of Medical Oncology, Ankara, TURKEY
7Gaziantep Medical Park Hospital, Gynecologic Oncology Clinic, Gaziantep, TURKEY

Keywords: Carboplatin, Chemotherapy, Ovarian epithelial carcinoma, Paclitaxel, Survival
This study aims to compare efficacy of dose dense and conventionally dosed paclitaxel-carboplatin regimens in the first-line treatment of epithelial ovarian cancer (EOC). We evaluated the medical records of women with EOC followed in Zekai Tahir Burak Women’s Health Training and Research Hospital between 2007-2019 retrospectively. The patients with Eastern Cooperative Oncology Group
Performance Status of 0-1-2, and stages of IC-IV, without previous treatments, who had undergone primary cytoreductive surgery were included. All patients had received either dose dense paclitaxel-carboplatin (paclitaxel 80 mg/m2 given on days 1, 8, and 15 plus carboplatin Area Under the Curve: 5 on day 1 of the 21 day cycle) or conventionally dosed paclitaxel-carboplatin (paclitaxel 175 mg/m2
plus carboplatin Area Under the Curve: 5 on day 1 of the 21 day cycle) regimens in the first line treatment. Baseline clinicopathological features, progression-free survival, and overall survival were evaluated. This study included data of 133 patients. Forty patients had received dose dense regimen while 93 had conventionally dosed regimen. Median progression-free survival of the dose dense group
[34.4 months (31.7 - 37.03)] was significantly longer than the conventional group [25.5 months (19.9-30.9)] [HR= 0. 55 (95% CI, 0.31 - 0.95), p= 0.03]. Median overall survival was 88.2 months (28.3 - 148.3) in the dose dense group and 76.5 months (63.3 - 89.7) in conventional group (p= 0.102).We have found improved progression-free survival in the first-line treatment of EOC with dose dense regimen compared to conventionally dosed regimen. Overall survival was longer in the dose dense group despite being not significant.